MEDSNasdaqWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends December 31

DataMeds AI, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 17, 2026

$2.67+0.04 (+1.52%)

Close on Oct 19, 2026

Market cap: $6.87M
P/E (TTM): –
Dividend yield: –

DataMeds AI, Inc. balance sheet

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Cash & Equivalents	0.04	1.03	0.00	–
Cash & Short-Term Investments	0.04	1.03	0.00	–
Receivables	1.14	2.72	–	–
Inventory	1.64	9.52	–	–
Prepaid Expenses & Other	–	0.00	–	–
Total Current Assets	2.82	15	0.34	–
Property, Plant & Equipment	0.23	0.39	–	–
Gross Property, Plant & Equipment	1.51	1.51	–	–
Accumulated Depreciation	-1.28	-1.12	–	–
Machinery & Equipment	0.59	0.59	–	–
Equity Method Investments	–	0.02	–	–
Operating Lease Right-of-Use Assets	0.97	1.53	–	–
Goodwill	14	16	–	–
Intangible Assets	2.50	1.62	–	–
Other Long-Term Assets	–	1.44	–	–
Total Assets	30	57	0.34	–
Current Portion of Long-Term Debt	–	11	0.35	–
Current Debt	11	12	0.35	–
Current Portion of Leases	0.57	0.52	–	–
Other Current Liabilities	0.23	–	–	–
Total Current Liabilities	30	38	2.89	–
Long-Term Debt	13	11	–	–
Long-Term Leases	0.53	1.10	–	–
Operating Lease Liabilities	1.17	1.78	–	–
Total Liabilities	43	51	3.24	–
Total Debt	23	23	0.35	–
Common Stock	0.00	0.01	0.00	–
Additional Paid-In Capital	99	16	0.00	–
Retained Earnings	-111	-9.76	-2.90	–
Shareholders' Equity	-12	6.73	-2.90	-0.01
Total Equity	-12	6.73	-2.90	-0.01
Total Liabilities & Equity	30	57	0.34	–
Shares Outstanding(shares)	2.03	1.02	0.89	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: -90.6%
Operating margin: -875.7%
Net margin: -1100.3%
Return on equity, FY2025: 3545.2%

Financial strength

Current ratio: 0.14
Debt to equity: -1.63
Debt to assets: 97.1%
Cash to current liabilities: 6.2%

Valuation

P/E ratio: –
Price to sales: 0.86
Price to book: –
Dividend yield: –